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Multimodality therapy for solid tumors is based on astrategy of cytoreduction of the primary tumor by
surgery, radiation, or ablative therapy. Adjuvant therapy,
usually involving chemotherapy, radiotherapy, or biologics,
is then used with the goal of completing the cytoreductive
process by eliminating micrometastatic disease remaining at
the local margins and/or disseminated systemically via he-
matogenous and lymphangitic routes. The selection of mo-
dalities for a given malignancy is based on the observed
locoregional and/or systemic patterns of recurrence. Thera-
peutic impact is dependent on the initial tumor burden and
disease stage at the time of therapy and the availability of
effective primary and adjuvant modalities.
For malignant pleural mesothelioma (MPM), available
local and systemic modalities have been inadequate to effect
a cure, and the goal of therapy is thus to improve the quality
and duration of life. In this regard, multimodality therapy
based on surgical cytoreduction has resulted in life extension
for selected patients relative to single-modality or palliative
treatments.
The time interval between treatment and death from
recurrent MPM is proportionate to the number of viable cells
remaining at the completion of therapy. In this sense, maxi-
mal collective cytoreduction is a major contributor to life
extension and should be a primary goal of therapy. In the
context of multimodality therapy, the primary goal of surgery
should be to obtain a macroscopic complete resection (MCR).
The focus of adjuvant modalities is primarily local, based on
a recurrence pattern dominated by ipsilateral hemithorax and
abdomen, and is secondarily systemic.
The choice of therapy for a given patient must also
reflect the knowledge that therapeutic impact is offset by the
risk and injury imparted by the modalities used. Patients for
whom the risks associated with obtaining MCR are prohibi-
tive may still be treated surgically with palliative intent, such
as to relieve dyspnea. Treating for palliation involves know-
ingly leaving behind significant tumor burden, which likely
lessens the effectiveness of subsequent adjuvant treatment.
For appropriately selected patients, treating with curative
intent (i.e., quality life extension) involves achieving MCR
followed by adjuvant therapeutic modalities capable of com-
pleting the cytoreductive process.
Whether extrapleural pneumonectomy (EPP) or pleu-
rectomy/decortication (P/D) is the preferred surgical ap-
proach to resectable MPM is a topic of ongoing debate.
Although EPP is associated with a higher morbidity (25%)
and surgical mortality (4–15%), it provides more complete
tumor cytoreduction than P/D, and the empty thorax permits
the use of high-dose radiotherapy postoperatively. P/D, by
contrast, is associated with lower morbidity and mortality
(1–5%), but MCR is less frequently attainable. Unresected
tumor bulk can remain in the diaphragm, pericardium, seg-
mental lobar fissures, and lymph nodes (intrapulmonary and
extrapleural). Diffuse tumor infiltration of pulmonary paren-
chyma is common with sarcomatoid and mixed histologic
variants.
In a few cases with favorable tumor distribution, me-
ticulous pleurectomy can result in MCR. The most favorable
circumstance is characterized by minimal or regionally lo-
cated disease, disease-free incomplete fissures, and soft epi-
thelial cell type. MCR often can be attained under somewhat
less favorable circumstances by combining P/D with adjunc-
tive intraoperative therapy (laser, cautery, intracavitary che-
motherapy).
With EPP, MCR can be achieved in most cases. The
lung, diaphragm, and pericardium are resected, and a com-
plete nodal dissection can be accomplished. The remaining
disease interface comprises the endothoracic fascia and the
mediastinum. We have found that this operation can be
accomplished in appropriately selected patients with accept-
able mortality (11 of 328 patients, 3.4%) and manageable
morbidity with vigilant postoperative monitoring.1
EPP forms the basis of a tri-modality treatment regimen
with adjuvant chemotherapy and radiotherapy.2 Adjuvant
treatment is scheduled using a “sandwich” design. Two
cycles of chemotherapy are followed by 35-Gy external beam
radiotherapy (with boosts to 55 Gy in marginal areas of
particular concern), followed by two additional cycles of
chemotherapy. Tumor involvement of lymph nodes outside
the pleural envelope and tumor detected at the parietal,
mediastinal, diaphragmatic, and pericardial resection margins
were found to be negative prognostic factors for survival.
These findings led us to propose a revised staging system
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based on surgical and pathologic variables for patients un-
dergoing treatment based on the paradigm of MCR with
additional local and systemic therapy. This staging system
significantly stratified survival of patients treated with tri-
modality therapy. Median survival ranged from 16 months
for patients with advanced-stage disease to 25 months for
patients with early-stage disease. These results suggest a
survival advantage for patients whose tumors are amenable to
surgical resection relative to those treated with chemother-
apy, for which pemetrexed/cisplatin is associated with a
12-month median survival3, or to palliative care with a
7-month median survival.4
Baldini et al.5 investigated sites of initial disease recur-
rence in this patient population and found that most patients
recurred locally in the ipsilateral hemithorax or abdomen.
Isolated distant failures were uncommon, and the authors
concluded that more effective methods of controlling local
disease were needed after MCR. This conclusion has been
confirmed by other investigators and has led to the investi-
gation of high-dose adjuvant radiation6 and intensity-modu-
lated radiotherapy.7
We have been investigating a strategy of MCR with
intraoperative heated intracavitary cisplatin chemotherapy.
Intracavitary therapy has a pharmacokinetic advantage, per-
mitting higher chemotherapy doses than those possible with
systemic infusion. This strategy has been found to be effec-
tive in treating abdominal malignancies including peritoneal
mesothelioma. We have conducted several phase I/II trials
examining either EPP or P/D as the cytoreductive procedure
and either sodium thiosulfate or amifostine for systemic
protection from cisplatin toxicity. A dose-escalation design
was used to determine a maximal tolerated dose.
Each of these treatment regimens has specific advan-
tages in select subsets of patients. From a surgical perspec-
tive, the method of achieving cytoreduction is not as impor-
tant as the ability to achieve MCR. Ongoing clinical trials that
compare the effectiveness of EPP versus P/D in combination
with various adjuvant therapeutic regimens are key to the
strategy of extending survival in MPM by matching optimal
treatment regimens with receptive subsets of patients.
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